General Info
Host: | HEK293 cells |
Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: | 2019-nCoV Spike RBD-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
Formulation: | Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. Contact us for customized product form or formulation. |
Immunoreactivity: | Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2 Spike RBD at 2 Mu g/mL (100 Mu L/well) can bind Human ACE-2 with a linear range of 0.001-2.96 ng/mL.2. Immobilized human ACE2 on COOH Chip, can bind SARS-COV-2 Spike RBD Pr |
Information
Immunogen Region: | RBD |
Immunogen: | Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Arg319-Phe541) of SARS-COV-2 (2019-nCoV) Spike RBD-His (Accession #YP_009724390.1) fused with a 6×H |
Description
Background | Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Arg319-Phe541) of SARS-COV-2 (2019-nCoV) Spike RBD-His (Accession #YP_009724390.1) fused with a 6×His tag at the C-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance